GSK

GSK plc

34.59
USD
0.67%
34.59
USD
0.67%
28.46 46.97
52 weeks
52 weeks

Mkt Cap 87.02B

Shares Out 2.52B

Chat
Send me real-time posts from this site at my email

GSK Jemperli meets main goal of phase 2 trial to treat lung cancer

GSK (NYSE:GSK) said its medicine Jemperli (dostarlimab) met the main goal of showing objective response rate (ORR) in certain patients with non-small cell lung cancer (NSCLC) in a phase 2 trial. The study, dubbed PERLA, evaluated Jemperli in combination with chemotherapy versus Merck's (NYSE:MRK) Keytruda (pembrolizumab) in combination with chemotherapy in first-line patients with metastatic NSCLC, the company noted in an Oct. 5 press release. The British pharma giant said that the PERLA study, which included 243 patients, was was not designed to show superiority and is the largest global head-to-head trial of programmed death receptor-1 (PD-1) inhibitors in this population. Jemperli is currently approved in the U.S. to treat adults with recurrent or advanced endometrial cancer in a second-line setting. GSK added that the safety and tolerability profile of Jemperli in the PERLA study was consistent with previous trials of similar regimens. The most common treatment-emergent adverse reactions were anemia, asthenia (weakness), nausea, constipation, cough, dyspnoea (breathing difficulty) vomiting, decreased appetite, and neutropenia (low levels of a type of white blood cell called neutrophils). Full results from the study, including the main goal of ORR and the key secondary goal of progression-free survival, with results by programmed death ligand-1 (PD-L1) expression subgroups, will be presented at an upcoming scientific meeting, GSK added. In addition, GSK said that was advancing both arms of a a study called COSTAR Lung into phase 3 after the recommendation of the data monitoring committee, as the trial met its expansion criteria per protocol. The COSTAR Lung phase 3 trial is a 3-arm trial comparing cobolimab plus dostarlimab plus docetaxel to dostarlimab plus docetaxel to docetaxel alone in patients with advanced NSCLC who have progressed on prior anti-PD-L1 therapy and chemotherapy.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue